The estimated financial toll of chikungunya is $50 billion, with $25 billion each spent on chronic disease and on acute illness.
The authors of the pandemic readiness report point to surges of H5N1 in mammals and of mpox deaths in DR Congo children as some of the latest threats in the face of preparedness gaps.
On average, the 102 joint-pain patients reported pain for over 4 months.
The recommendation applies to people traveling to outbreak areas and others at extra risk from the virus.
The study underscores the need for equitable access to vaccines, effective drugs, and mosquito-control efforts, the authors say.
The vaccine is the first of its kind against chikungunya, a high-burden disease that is spreading to new areas.
Several of the El Nino health risks are due to water contamination, either from flooding or drought. Malnutrition due to food insecurity was the top threat.
ACIP topics include RSV, flu, polio, mpox, meningococcal, and COVID-19 vaccines.
A single dose of the vaccine candidate triggered neutralizing antibody production in 98.9% of recipients 28 days later.
Dengue in the Americas is outpacing 2022 activity by 12%, and chikungunya is also on the rise.
